Shire (LON: SHP)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group in a research note issued to investors on Tuesday. They currently have a $38.57 (2400 GBX) price target on the stock.

A number of other firms have also recently commented on SHP. Analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of Shire in a research note to investors on Tuesday, January 8th. They now have a $35.46 price target on the stock. Separately, analysts at AlphaValue reiterated a “buy” rating on shares of Shire in a research note to investors on Wednesday, October 31st. They now have a $34.37 price target on the stock. Finally, analysts at Barclays Capital reiterated an “overweight” rating on shares of Shire in a research note to investors on Tuesday, October 30th. They now have a $36.88 price target on the stock.

Shire opened at 2026.00 on Tuesday. Shire has a 52-week low of GBX 1682.00 and a 52-week high of GBX 2316.00. The stock’s 50-day moving average is currently GBX 1877.. The company’s market cap is £11.263 billion.

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.